Targeting CAF-derived cytokines and chemokines in combination with immunotherapies can improve anticancer efficiency such as when targeting the CXCL12-CXCR4 axis reverses FAP + CAF-mediated immunosuppression and synergizes with anti-PD-L1 immunotherapy in pancreatic cancer [68]. This evidence concerns the gene CXCL12 and pancreatic neoplasm.